Paris, France – July 9, 2026. Ipsen (Euronext: IPN; ADR: IPSEY) announced topline results today from its Phase III BEOND program testing Dysport® (abobotulinumtoxinA) as a preventive treatment for migraine.
Both trials in the program, E-BEOND for episodic migraine and C-BEOND for chronic migraine, hit their primary goal of reducing monthly migraine days compared with placebo.
A First For Episodic Migraine
No botulinum toxin has previously shown statistically significant results in a Phase III episodic migraine trial. E-BEOND breaks that pattern. Combined with the C-BEOND findings, the BEOND program marks the first time a single Phase III effort has shown a botulinum toxin working in both migraine types at once, rather than one or the other.
Safety Profile
Across both studies, Dysport’s safety data lined up with what’s already documented for the drug in its approved uses. Researchers did not identify any new or unexpected safety signals during the trials.
Why This Distinction Matters?
Episodic and chronic migraine are classified by frequency, not severity. The E-BEOND trial defined episodic migraine as up to 14 headache days a month, with at least 6 qualifying as migraine days. Chronic migraine is set at 15 or more headache days monthly, with at least 8 as migraine days. Far more patients fall into the episodic category, and until now, treatment development for botulinum toxin therapies has concentrated on the chronic form. A therapy validated across both categories opens the door to a much larger patient population than prior botulinum toxin migraine treatments have addressed.
What Researchers Are Saying?
Christelle Huguet, Ipsen’s EVP and Global Head of R&D, described the results as a meaningful step forward for botulinum toxin research in migraine treatment.
She pointed to BEOND’s dual success in episodic and chronic migraine as evidence that Dysport could become a first-in-class option for a wider range of patients than existing therapies reach.
Dr. Cristina Tassorelli, who chairs neurology at the University of Pavia and served as principal investigator on C-BEOND, said the topline data mark Dysport as the first botulinum toxin shown effective in both forms of migraine prevention, which she called a step forward for patients’ treatment choices.
Dr. Jessica Ailani, who directs the MedStar Georgetown Headache Center and led the E-BEOND trial, noted that few preventive options currently exist for episodic migraine sufferers. She said the results point toward a possible new preventive therapy that, pending approval, could help a wide range of patients.
Ipsen plans to present full BEOND data at an upcoming scientific conference.
Trial Design
The BEOND program ran as two separate randomized, multicenter, placebo-controlled studies: C-BEOND (registered as NCT06047444) and E-BEOND (registered as NCT06047457). Combined, the trials enrolled 1,510 patients across 120 sites. Both studies measured the same primary endpoint: change in monthly migraine days from baseline, assessed at week 24 using data from weeks 21 through 24. An extension phase, during which every participant receives Dysport for two treatment cycles, will run through week 48.
About Migraine
Migraine affects an estimated 14% of people worldwide, making it one of the most common neurological conditions globally. Symptoms include throbbing head pain, nausea, vomiting, and heightened sensitivity to light, sound, touch, and smell, often with effects that extend well beyond the person experiencing them to their families. Clinicians classify the condition as episodic (up to 14 headache days monthly, at least 6 involving migraine) or chronic (15 or more headache days monthly, at least 8 involving migraine).
About Dysport
Dysport (abobotulinumtoxinA) is an injectable botulinum neurotoxin type A product derived from Clostridium bacteria. It works by blocking nerve signal transmission to reduce muscle contractions and ships as a lyophilized powder. The drug holds marketing authorization in roughly 90 countries, has over three decades of clinical use behind it, and accounts for more than 21 million patient treatment-years. Full usage guidance appears in the Summary of Product Characteristics and the U.S. Prescribing Information. Approved indications and labeling vary by country.
About Ipsen
Ipsen is a global biopharmaceutical company focused on oncology, rare disease, and neuroscience. Built on nearly a century of drug development experience, the company operates from hubs in the U.S., France, and the U.K., with teams across more than 40 countries and medicines reaching patients in over 100 countries. Ipsen trades on Euronext Paris (IPN) and through a Sponsored Level I American Depositary Receipt program in the U.S. (IPSEY).
